Supporting patient groups and continuously improving knowledge in our therapy areas is part of our corporate responsibility.
Our ultimate goal is to discover and develop innovative therapies to improve patients' quality of life.
We specialize in the treatment of life-threatening diseases. Our patients always come first.
Awards, Grants & Initiatives
New and exciting opportunities allow us to address previously unmet patient needs and these continue to drive us each day.
At CSL Behring, we work every day as if someone’s life depends on it, because it does.
CSL Behring's biotherapeutics are manufactured in state-of-the-art facilities under strictly controlled conditions.
Help us deliver on our promise to save lives and protect the health of people.
We want you to feel comfortable at CSL.
Get to know us and learn more about people, projects and what happens in the world of CSL Behring.
Information for the press, such as press releases and press contact.
Popular search terms:
CSL Limited delivered full-year net profit of $2.375 billion.
The city of Marburg hails the accomplishments of its biotech sector with new video.
A semester abroad during my dual studies at CSL Behring.
CSL Behring management welcomes Australian Ambassador to Germany Philip Green.
Video: “Topping-out” milestone celebrated in Marburg for facility scheduled to open in 2022.
From immune system problems to bleeding disorders and more – plasma-based therapies treat many health conditions.
CSL closes commercialization and license agreement for Hemophilia B gene therapy.
The future of rare disease diagnostics in the focus of science and industry
Last year’s “Cents for a good cause” will benefit children and young people with mental illnesses.
Americas
Asia Pacific
Middle East
Europe
